HIV-2 Genetic Diversity in France

Bissau. 2. -. Burkina-Faso. 1. -. Cape-Verde. 5. -. Congo. -. 1. Côte d'Ivoire. 2. 5. France. 3. 2. Ghana. 1. -. Mali. 5. 2. Morocco. 1. -. Martinique. -. 1. Poland. 1.
30KB taille 0 téléchargements 362 vues
HIV-2 Genetic Diversity in France

F. Simon D. Descamps S. Souquière S. Matheron

F. Damond C. Apetrei A. Leprêtre F. Brun-Vézinet

Hôpital Bichat Claude Bernard - Paris and the French National HIV-2 Cohort

HIV-2 : 6 subtypes designated A to F •

2 major HIV-2 subtypes : A and B A endemic in West Africa B mainly in Côte d’Ivoire and Mali Inter-subtype A and B recombinants



4 minor HIV-2 subtypes : C to F Liberia and Sierra-Leone, highly divergent from subtypes A and B (>25% Gag and Env)

HIV-2 genetic diversity in France Objectives : - to study the prevalence of HIV-2 subtypes in France - to study the clinical and biological consequences of this diversity - to investigate the relation between HIV-2 diversity and serological reactivity

Patients and Methods 40 HIV-2-infected patients living in France : - 39 from the French ‘HIV-2 prospective cohort’ - 1 patient falsely negative by a third-generation EIA

-DNA extracted from fresh uncultured lymphocytes - Integrase-LTR XL PCR - followed by env nested PCR using different set of prime LTR

Integrase

ENV

POL EB0

EB2

EB4

EB6

EB7

EB5 Env A

Env C Env E

Env F Env D Env B Env G

V3 LOOP

TM

DNA- HIV-2 amplification - 40 patients Age 41 ± 11 19 M and 17 F CD4+ = 304 ± 239/ml - 36 strains PCR-positive between C2-V3 and gp 41 were sequenced.

- 4 patients with CD4 > 500 : amplification failed

HIV-2 diversity in France HIV-2 subtype Patients’ origin Bissau Burkina-Faso Cape-Verde Congo Côte d’Ivoire France Ghana Mali Morocco Martinique Poland Senegal

A

B

2 1 5 2 3 1 5 1 1 3

1 5 2 2 1 1

24

12

HIV-2 diversity in France subtype A

subtype B

N

24

12

Age

40 ± 10

41 ± 12

CD4+ Clinical status A B C

290 ± 240

330 ± 245

19 (79%) 1 4

9 (75%) 1 2

9/10 5/9 1/5

4/5 3/5 0/2

Positive viremia CD4/µl < 200 200-500 >500

B

UC1

97378 D205 96339

EHOA MM251

UC1 97227 96309 96306

BEN SYK

9644 96307

AGM677 SAB1C

EHOA

AGMTYO

63 96

SIVmnd

96150 SMMpbj MM142

99

ROD 96327

100 MM151 90

ROD

72

96199

61 95

96202

91 96326 96205

A’

96324

96330

96325 96226 96310 97223 9649 96151 96201 96323 BEN 96328 95152

96207

A HIV-2 gp41 : Phylogenetic analysis, neighbor-joining

Genetic distance between HIV-2 subtypes Amino-acids A

A

B

A’

7±1 (3.9–8.8) 9±2

A’

11 ± 1 (7.6-14.3)

(3.8–12.7)

B

18 ± 2

18 ± 2

9±3

(13.7-21.9)

(15-21)

(2.9-14.5)

SIVsm

16 ± 1 (15.1-18.2)

17 ± 1 (15.9-18)

20 ± 1 (18.7-22.7)

HIV-2 subtypes A and B reactivity on HIV-1peptides

Number of reactive sera HIV-1 gp 41 peptide M

O

non M-non O

SIVcpz

(n=7)

0

0

0

0

A' (n=13)

0

0

0

0

B (n=12)

4

1

3

5

A HIV-2 sera

HIV-2 subtype B sera cross-react more frequently on HIV-1 gp41 peptides

H IV -2 subtype B cross re activity on H IV -1 immunodominant domain A : ROD

QQQQQLLDVVKRQQELLRLTVWGTKNLQARVTAI EKYLQDQARLNSWGCAFRQVCH

A :

. . . . . . . . . . . . . . . M. . . . . . . . . . . . . . . . . . . . . . K. . . Q. . . . . . . . . . . . .

B :

. . . . . . . . . . . . . . . L. . . . . . . . . . . . T. . . . . . . . . K. . . L. . . . . . . . . . . . .

SIVsm

. . . . . . . . . . . . . . . L. . . . . . . . . . . . T. . . . . . . . . K. . . Q. . . . . . . . . . . . .

STM

...............

AGMSab1

. . . KN. . AA. EQ. . QM. K. . I . . V. . . N. . . . L. . . . E. . . . . . I . . . . WK. . . .

SIVmnd

. . K. - . . KLI EQ. S. L. K. . I . . V. . . . T. L. SL. N. I K. . . L. SQ. . . SWA. . . . V. . . N. . RAI EA. . HL. Q. . . . . I . Q. . . . . L. V. R. . K. . L. GI . . . SGKKI . -

HIV V- 1 gr oup M

L. . . . . . . . . . . . T. . . . . . . . . K. . . Q. . . . . . . . . . . . .

HIV-2 sensitivity to antiretroviral drugs in vitro

nevirapine S

indinavir 9

ritonavir 4

saquinavir 9

A R

9

5

subtype S

6

3

6

1

4

1

B R

7

Phenotyic susceptibility of 9 subtype A and 7 subtype B strains IC50 determination R : IC50 at least 4 times higher than HIV-1 subtype B IC50

HIV-2 genetic diversity in France Conclusions

•Both subtypes A and B are cocirculating in France •Both subtypes A and B are pathogenic in vivo •HIV-2 subtype B has been present in Côte d’Ivoire since at least 1982 •One sample corresponding to a ‘distant’ subtype B was falsely negative by a third-generation HIV-1/2 screening EIA

HIV-2 genetic diversity in France Conclusions

• subtypes A et B have a phylogenic double-star configuration • Phylogenetic positions correlated with the geographical origin of the strains, in accordance with phenetic analysis (B.Korber)

• Sera from subtype B-infected patients are strongly cross-reactive on the HIV-1 immunodominant domain, even by Western-Blot

• HIV-1/HIV-2 dual reactivity in West-African patients could be explained at least in part by HIV-2 subtype B infection